Media in the Middle - Pharmaceutical Executive

ADVERTISEMENT

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
Media in the Middle


Pharmaceutical Executive


Information Flow Chart
As the distinction between pharma and biotech blurs, so, too, does the distinction between investor relations (IR) and public relations (PR) agencies serving those industries. The recent merger of PResence Euro RSCG and IR mainstay Noonan/Russo into the newly named Noonan/Russo PResence Euro RSCG (NRP) may best represent the agency world's attempt to unify-and theoretically, strengthen-its clients' financial, corporate, and product messages for a growing list of audiences. But most interesting may be the role played by agencies' most important audience-the media-which finds itself in the middle of an unusual flow of information fraught with potential conflicts of interest.

Freelance reporters are the "eyes and ears" of the Grassroots Research Group (GRG) of investment company Dresdner RCM, a part of the giant German insurer Alliance, whose clients' assets are valued at nearly one trillion euros. Misha Derkavski, GRG's director, says journalists have played a significant role in creating the company's healthcare analyst reports for nearly 20 years.

"They gather information simply by talking to knowledgeable sources who are not related to the financial industry," he explains. "That includes practicing physicians, clinical investigators, and other healthcare providers."

Ian Vose, global director of research, uses a recent GRG study designed to assess the changing market dynamics for Genzyme's renal disease treatment Renagel (sevelamer) to describe how the group adds value to analysts' investment advice.

"The drug's growth slowed a bit at the end of the fourth quarter," says Vose, "and there was some concern about whether that was the beginning of a trend or just an anomaly. So we talked to nephrologists to see if they planned to use more or less Renagel, if their use had plateaued, and how they felt about a competitor entering the market within the next year."

Vose, Derkavski, and Michael Dauchot, lead healthcare analyst at Dresdner, all say they go to great lengths to avoid journalistic bias in designing surveys and reviewing reporters' results. But it's unlikely that reporters involved in GRG maintain objectivity when they are bombarded by information from the very companies whose products they're assigned to research. Reporters' choices of survey subjects-doctors and other prescribers who may have been influenced by corporate PR and marketing campaigns-may be biased and may exclude subjects with different perspectives of the product or company.

Nevertheless, the Dresdner team says, trusted management contacts provide them with insights into companies that often reveal problems and difficult issues. That doesn't mean it won't recommend investment in a company with problems. In fact, if a company has a proven track record and its leadership has been honest and open about those problems, it may still fall into the "buy" category.

Derkavski says that, by reconciling the views of doctors, managed care providers, and pharma companies, they can better assess the complex interplay of forces affecting the industry. That philosophy, says NRP's executive vice-president and general manager Nancy Rueth, captures the future of corporate and product communications in which the media is part of the process, not just a target for information.

ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
FindPharma Careers
Source: Pharmaceutical Executive,
Click here